23948sdkhjf
  • {{ window.visitor.corporateClient.name }}
    Företagslösning
    {{ window.visitor.ipAccess.corporateClient.name }}
    {{ window.visitor.corporateClient.name }}

  • Välkommen till vår företagslösning

    Här kan du administrera användarna i din företagslösning.

  • Välkommen till din prenumeration för Life Science Sweden.

  • Welcome to our Corporate client solution

    Your IP is registered with the company mentioned above and provides access to Life Science Sweden.

  • Click here to go to sign-up
Logga in eller skapa en prenumeration för att spara artiklar
Få tillgång till allt innehåll på Life Science Sweden
Ingen bindningstid eller kortinformation krävs
Prova Life Science Sweden nu
Gäller endast personlig prenumeration.
Kontakta oss för en företagslösning.
Annons
Annons
News in English

AlzeCure Signs Billion-Dollar Deal with Lilly

AlzeCure, a Huddinge-based biotech company, has signed a licensing agreement with Eli Lilly for one of its Alzheimer’s drug candidates.
Annons

AlzeCure, which operates in Flemingsberg near Karolinska Institutet Huddinge, develops treatments for conditions including Alzheimer’s disease and neuropathic pain. The company has now announced that it is licensing its Alzstatin candidate, ACD680, to the US pharmaceutical giant Eli Lilly.

ACD680 is being developed as a treatment for Alzheimer’s disease and works by reducing the production of the harmful amyloid-beta protein Aβ42. The compound is also designed to increase the production in the brain of harmless amyloid-beta proteins that may help reduce the aggregation of amyloid plaques.

Annons Annons
BREAKING
{{ article.headline }}
0.094|